机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, P.R. China[2]Department of Ophthalmology, West China Hospital Sichuan University, Chengdu, P.R. China四川大学华西医院[3]Key Laboratory of Photochemical Conversion and Optoelectronic Material, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, P.R. China
Milk exosomes have also been widely used as emerging delivery vehicles for various therapeutic cargoes. Retinoblastoma (RB) is the most common primary intraocular malignancy of childhood. However, the therapeutic efficacy is severely hampered by the presence of blood-retinal barrier (BRB) and systemic side effects. Legumain (LGMN) can be used as a target for tumor microenvironment responsive delivery design and therapeutic applications. Here, a LGMN-sensitive peptide KC26-modified milk exosomes loaded with carboplatin (CBP-KC26-MExos). The system enables milk exosomes loaded with carboplatin (CBP) to reach the target cells by binding to LGMN, improves tumor targeting, enhances cellular uptake and apoptosis, inhibits cell proliferation, invasion and migration. Intravenous injection of CBP-KC26-MExos cross the BRB significantly inhibited intraocular tumor progression and reduced CBP toxicity. We have developed a 'drug-target-carrier' approach and proposed an enzyme sensitive peptide (KC26) modified milk exosomes loaded with CBP, providing a perspective for exploring targeted therapy of tumor cells and tumor microenvironment, and offering a promising clinical strategy for the treatment of retinoblastoma.
基金:
This research was supported by the Open Project of Tianjin Key Laboratory of Retinal Functions and Diseases (2021tjswmm001), Tianjin Health Science and Technology Project (TJWJ2022MS012), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-037A) and Beijing Natural Science Foundation (L222091).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|4 区医学
小类|4 区药学
最新[2025]版:
大类|4 区医学
小类|4 区药学
第一作者:
第一作者机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, P.R. China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Hetong,Wang Wei,Tang Qin,et al.Enzyme-sensitive peptide KC26 modifies milk exosomes encapsulating carboplatin for the treatment of retinoblastoma[J].Pharmaceutical Development And Technology.2025,1-11.doi:10.1080/10837450.2025.2505005.
APA:
Wang Hetong,Wang Wei,Tang Qin,Liu Xun,Zhu Limin...&Lin Tingting.(2025).Enzyme-sensitive peptide KC26 modifies milk exosomes encapsulating carboplatin for the treatment of retinoblastoma.Pharmaceutical Development And Technology,,
MLA:
Wang Hetong,et al."Enzyme-sensitive peptide KC26 modifies milk exosomes encapsulating carboplatin for the treatment of retinoblastoma".Pharmaceutical Development And Technology .(2025):1-11